Batu Biologics Continues Fight In War Against Lung Cancer

SAN DIEGO--(BUSINESS WIRE)--Batu Biologics, an immuno-oncology company, has successfully completed its $1 million seed round of funding, bringing the company one step closer in its efforts to battle lung cancer, the leading cancer killer in the United States. Batu leveraged primarily private and angel funding to attain this fundraising goal.

Help employers find you! Check out all the jobs and post your resume.

Back to news